{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:35:29Z","timestamp":1783632929702,"version":"3.55.0"},"reference-count":37,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,8,1]]},"DOI":"10.2169\/internalmedicine.4981-20","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T22:08:24Z","timestamp":1627769304000},"page":"2451-2459","source":"Crossref","is-referenced-by-count":8,"title":["Neurofibromatosis Type 1 with Concurrent Multiple Endocrine Disorders: Adenomatous Goiter, Primary Hyperparathyroidism, and Acromegaly"],"prefix":"10.2169","volume":"60","author":[{"given":"Shigemitsu","family":"Yasuda","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bizzarri C, Bottaro G. Endocrine implications of neurofibromatosis 1 in childhood. Horm Res Paediatr 83: 232-241, 2015.","DOI":"10.1159\/000369802"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. National Institutes of Health Consensus Development Conference Statement. Neurofibromatosis. Arch Neurol Chicago 45: 575-578, 1988.","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med 12: 1-12, 2010.","DOI":"10.1097\/GIM.0b013e3181bf15e3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Cimino PJ, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol 148: 799-811, 2018.","DOI":"10.1016\/B978-0-444-64076-5.00051-X"},{"key":"5","unstructured":"5. Yoshida Y, Kuramochi A, Oota Y, et al. Clinical guidelines for neurofibromatosis type 1 (Recklinghausen disease) 2018. Nihon Hifukagakkai Zasshi 128: 17-34, 2018 (in Japanese)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Shapira S, Barkan B, Friedman E, Kloog Y, Stein R. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and RAS-independent pathways. Cell Death Differ 14: 895-906, 2007.","DOI":"10.1038\/sj.cdd.4402057"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356: 713-715, 1992.","DOI":"10.1038\/356713a0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Gottfried ON, Viskochil DH, Couldwell WT. Neurofibromatosis type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Neurosurg Focus 28: E8, 2010.","DOI":"10.3171\/2009.11.FOCUS09221"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44: 81-88, 2007.","DOI":"10.1136\/jmg.2006.045906"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Karajannis MA, Ferner RE. Neurofibromatosis-related tumors: emerging biology and therapies. Curr Opin Pediatr 27: 26-33, 2015.","DOI":"10.1097\/MOP.0000000000000169"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hannah-Shmouni F, Demidowich AP, Rowell J, Lodish M, Stratakis CA. Large pituitary gland with an expanding lesion in the context of neurofibromatosis 1. BMJ Case Rep 2017: bcr2017222411, 2017.","DOI":"10.1136\/bcr-2017-222411"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Checa Garrido A, del Pozo Pic\u00f3 C. Acromegaly and type 1 neurofibromatosis. Is association of both conditions due to chance? Endocrinol Nutr 60: 144-145, 2013.","DOI":"10.1016\/j.endoen.2012.01.014"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hozumi K, Fukuoka H, Odake Y, et al. Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1. Endocr J 66: 853-857, 2019.","DOI":"10.1507\/endocrj.EJ19-0035"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Petr EJ, Else T. Pheochromocytoma and paraganglioma in neurofibromatosis type 1: frequent surgeries and cardiovascular crises indicate the need for screening. Clin Diabetes Endocrinol 4: 15, 2018.","DOI":"10.1186\/s40842-018-0065-4"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kalkan E, Waguespack SG. Endocrine tumors associated with neurofibromatosis type 1, Peutz-Jeghers syndrome and other familial neoplasia syndromes. Front Horm Res 41: 166-181, 2013.","DOI":"10.1159\/000345676"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lee HM, Lee SH, Yang IH, et al. Acromegaly with normal insulin-like growth factor-1 levels and congestive heart failure as the first clinical manifestation. Endocrinol Metab 30: 395-401, 2015.","DOI":"10.3803\/EnM.2015.30.3.395"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ozawa A, Agarwal SK, Mateo CM, et al. The parathyroid\/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J Clin Endocrinol Metab 92: 1948-1951, 2007.","DOI":"10.1210\/jc.2006-2563"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 94: 1826-1834, 2009.","DOI":"10.1210\/jc.2008-2083"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Costa-Guda J, Marinoni I, Molatore S, Pellegata NS, Arnold A. Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J Clin Endocrinol Metab 96: E701-E706, 2011.","DOI":"10.1210\/jc.2010-1338"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. D\u0105browska AM, Tarach JS, Kurowska M, Nowakowski A. Thyroid diseases in patients with acromegaly. Arch Med Sci 10: 837-845, 2014.","DOI":"10.5114\/aoms.2013.36924"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Walther M.M, Herring J, Enquist E, Keiser HR, Linehan WM. Von Recklinghausen&apos;s disease and pheochromocytomas. J Urol 162: 1582-1586, 1999.","DOI":"10.1016\/S0022-5347(05)68171-2"},{"key":"22","unstructured":"22. Tokui N, Okamoto T, Imanishi K, et al. Adrenal pheochromocytoma with multiple neurofibromatosis on the trunk. Hinyokika Kiyo 58: 17-19, 2012 (in Japanese)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Okada E, Shozawa T. Von Recklinghausen&apos;s disease (neurofibromatosis) associated with malignant pheochromocytoma. Acta Pathol Jpn 34: 425-434, 1984.","DOI":"10.1111\/j.1440-1827.1984.tb07571.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Takayama T, Kato Y, Tsuru N, et al. A case of pheochromocytoma with von Recklinghausen&apos;s and review of 67 Japanese cases. Nihon Hinyokika Gakkai Zasshi 92: 479-483, 2001 (in Japanese).","DOI":"10.5980\/jpnjurol1989.92.479"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Favere AM, Tsukumo DM, Matos PS, Santos SL, Lalli CA. Association between atypical parathyroid adenoma and neurofibromatosis. Arch Endocrinol Metab 59: 460-466, 2015.","DOI":"10.1590\/2359-3997000000092"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kodama H, Iihara M, Okamoto T, Obara T. Water-clear cell parathyroid adenoma causing primary hyperparathyroidism in a patient with neurofibromatosis type 1: report of a case. Surg Today 37: 884-887, 2007.","DOI":"10.1007\/s00595-007-3484-x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Martini AE, Zolton JR, DeCherney AH. Isolated absent thelarche in a patient with neurofibromatosis type 1 and acromegaly. Obstet Gynecol 131: 96-99, 2018.","DOI":"10.1097\/AOG.0000000000002389"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Hannah-Shmouni F, Stratakis CA. Growth hormone excess in neurofibromatosis 1. Genet Med 21: 1254-1255, 2019.","DOI":"10.1038\/s41436-018-0312-1"},{"key":"29","unstructured":"29. Car\u015fote M, P\u0103un S, Neam\u0163u MC, et al. The immunohistochemistry aspects in two cases of neurofibromatosis-associated abdominal tumors. Rom J Morphol Embryol 53: 401-405, 2012."},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Ercolino T, Lai R, Giach\u00e8 V, et al. Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both <i>NF1<\/i> and <i>RET<\/i> genes. Gene 536: 332-335, 2014.","DOI":"10.1016\/j.gene.2013.12.003"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Gkaliagkousi E, Erlic Z, Petidis K, et al. Neurofibromatosis type 1: should we screen for other genetic syndromes? A case report of co-existence with multiple endocrine neoplasia 2A. Eur J Clin Invest 39: 828-832, 2009.","DOI":"10.1111\/j.1365-2362.2009.02174.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kamilaris CDC, Stratakis CA. Multiple endocrine neoplasia type 1 (MEN1): an update and the significance of early genetic and clinical diagnosis. Front Endocrinol 10: 339, 2019.","DOI":"10.3389\/fendo.2019.00339"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Josefson J, Listernick R, Fangusaro JR, Charrow J, Habiby R. Growth hormone excess in children with neurofibromatosis type 1-associated and sporadic optic pathway tumors. J Pediatr 158: 433-436, 2011.","DOI":"10.1016\/j.jpeds.2010.09.013"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Suojun Z, Feng W, Dongsheng G, Ting L. Targeting Raf\/MEK\/ERK pathway in pituitary adenomas. Eur J Cancer 48: 389-395, 2012.","DOI":"10.1016\/j.ejca.2011.11.002"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Dworakowska D, Wlodek E, Leontiou CA, et al. Activation of RAF\/MEK\/ERK and PI3K\/AKT\/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 16: 1329-1338, 2009.","DOI":"10.1677\/ERC-09-0101"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Agarwal SK, Ozawa A, Mateo CM, Marx SJ. The MEN1 gene and pituitary tumours. Horm Res 71: 131-138, 2009.","DOI":"10.1159\/000192450"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Taguchi R, Yamada M, Horiguchi K, et al. Haploinsufficient and predominant expression of multiple endocrine neoplasia type 1 (MEN1)-related genes, MLL, p27Kip1 and p18Ink4C in endocrine organs. Biochem Biophys Res Commun 415: 378-383, 2011.","DOI":"10.1016\/j.bbrc.2011.10.077"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/15\/60_4981-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T05:00:45Z","timestamp":1628312445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/15\/60_4981-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":37,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4981-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,1]]},"article-number":"4981-20"}}